Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014; 28: 525–542.

    Article  CAS  PubMed  Google Scholar 

  2. Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–264.

    Article  CAS  PubMed  Google Scholar 

  3. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568–571.

    Article  CAS  PubMed  Google Scholar 

  4. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563–567.

    Article  CAS  PubMed  Google Scholar 

  5. Rosenblatt J, Avivi I, Vasir B, Uhl L, Katz T, Somaiya P et al. Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation. ASH Annual Meeting Abstracts 2012; 120: 578.

    Google Scholar 

  6. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007; 110: 296–304.

    Article  CAS  PubMed  Google Scholar 

  7. Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 2013; 27: 464–472.

    Article  CAS  PubMed  Google Scholar 

  8. Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010; 116: 2286–2294.

    Article  CAS  PubMed  Google Scholar 

  9. Hallett WH, Jing W, Drobyski WR, Johnson BD . Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transpl 2011; 17: 1133–1145.

    Article  CAS  Google Scholar 

  10. Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 2013; 19: 3640–3648.

    Article  CAS  PubMed  Google Scholar 

  11. Kearl TJ, Jing W, Gershan JA, Johnson BD . Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J Immunol 2013; 190: 5620–5628.

    Article  CAS  PubMed  Google Scholar 

  12. Paiva B, Vidriales MB, Rosinol L, Martinez-Lopez J, Mateos MV, Ocio EM et al. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia 2013; 27: 2056–2061.

    Article  CAS  PubMed  Google Scholar 

  13. Radl J, Croese JW, Zurcher C, Van den Enden-Vieveen MH, de Leeuw AM . Animal model of human disease. Multiple myeloma. Am J Pathol 1988; 132: 593–597.

    CAS  PubMed Central  PubMed  Google Scholar 

  14. Murillo O, Arina A, Hervas-Stubbs S, Gupta A, McCluskey B, Dubrot J et al. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res. 2008; 14: 6895–6906.

    Article  CAS  PubMed  Google Scholar 

  15. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA . Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013; 19: 997–1008.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by the Cooperative Research Thematic Network grants RD12/0036/0058 of the Red de Cancer (Cancer Network of Excellence); Instituto de Salud Carlos III, Spain, Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria (FIS: PI060339; 06/1354; 02/0905; 01/0089/01-02; PS09/01897/01370 and G03/136; Sara Borrell: CD13/00340); and Asociación Española Contra el Cáncer (GCB120981SAN), Spain. The study was also supported internationally by the International Myeloma Foundation Junior Grant Proposal and the Multiple Myeloma Research Foundation research fellow award.

Author Contributions

IM, JFSM, EMO and BP conceived the idea and designed the study. EMO, FE, AGC, AB and JFSM supplied study material or patients. BP and NP analyzed flow-cytometric data. LSS, IAM and IR performed immunophenotypic studies. AA, SL and AR performed mouse experiments. RS and BOO measured mouse serum immunoglobulin titers. BP and AA performed statistical analysis. BP, AA, JFSM and IM analyzed and interpreted the data. BP, AA, JFSM and IM wrote the manuscript. All authors reviewed and approved the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to B Paiva or I Melero.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Paiva, B., Azpilikueta, A., Puig, N. et al. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia 29, 2110–2113 (2015). https://doi.org/10.1038/leu.2015.79

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2015.79

This article is cited by

Search

Quick links